Everolimus is FDA-approved for five cancerous conditions including advanced RCC (2009), subependymal giant cell astrocytoma associated with tuberous sclerosis (2010), progressive neuroendocrine tumours of pancreatic origin (2011), advanced hormone receptor-positive HER2-negative breast cancer (2012), paediatric and adult patients with subependymal giant cell astrocytoma (2012), and neuroendocrine tumours of gastrointestinal or lung origin with unresectable, locally advanced or metastatic disease (2016). Here, NR4A1 is linked to neuroendocrine neoplasm.